Health Catalyst, Inc. (NASDAQ:HCAT) Short Interest Down 9.5% in July

Health Catalyst, Inc. (NASDAQ:HCAT) saw a large decline in short interest in July. As of July 31st, there was short interest totalling 2,200,000 shares, a decline of 9.5% from the July 15th total of 2,430,000 shares. Based on an average trading volume of 571,300 shares, the short-interest ratio is currently 3.9 days.

Health Catalyst Stock Performance

Shares of HCAT stock traded up $0.08 during trading hours on Monday, reaching $6.84. The company had a trading volume of 280,544 shares, compared to its average volume of 596,125. The company has a market capitalization of $403.80 million, a P/E ratio of -3.65 and a beta of 1.32. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $12.05. The stock’s fifty day simple moving average is $6.62 and its 200 day simple moving average is $7.17.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative net margin of 35.56% and a negative return on equity of 11.86%. The company had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. During the same period in the prior year, the company posted ($0.21) EPS. The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. As a group, equities analysts expect that Health Catalyst will post -0.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HCAT. Evercore ISI cut their target price on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Piper Sandler dropped their target price on Health Catalyst from $15.00 to $14.00 and set an “overweight” rating on the stock in a report on Thursday, June 6th. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 price objective on shares of Health Catalyst in a research report on Tuesday, May 21st. Stephens reduced their target price on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research note on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.50.

Insiders Place Their Bets

In related news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $6.19, for a total value of $32,243.71. Following the transaction, the chief operating officer now owns 150,006 shares of the company’s stock, valued at $928,537.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 13,035 shares of company stock worth $81,396 in the last 90 days. Corporate insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Several large investors have recently modified their holdings of the stock. Mackenzie Financial Corp bought a new stake in Health Catalyst during the fourth quarter valued at $172,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Health Catalyst by 23.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,072 shares of the company’s stock valued at $140,000 after buying an additional 2,817 shares during the last quarter. New York State Common Retirement Fund raised its stake in Health Catalyst by 1.3% during the fourth quarter. New York State Common Retirement Fund now owns 122,967 shares of the company’s stock worth $1,139,000 after acquiring an additional 1,582 shares during the period. Semanteon Capital Management LP bought a new position in Health Catalyst in the fourth quarter worth about $197,000. Finally, Valmark Advisers Inc. acquired a new position in Health Catalyst in the fourth quarter valued at approximately $1,204,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.